Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (10381)	7/2/1998 7:05:00 PM
From: blankmind	Read Replies (1) \| Respond to of 23519

- Yup - I can't believe we're on SB's radar screen - and stock this low. - Thanks. " Astra (Sweden) has obtained European Union marketing approval for Muse, a transurethral system for erectile dysfunction developed by Vivus. According to Mehta and Isaly, healthcare consultants, as many as 50 mil men in the US, Europe, and Japan and up to 140 mil men worldwide suffer from erectile dysfunction. Salomon Smith Barney predicts the drug will earn SwKr904 mil ($118 mil) on global sales in 2001."